C. Hodgson

发表

Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

James A. Williams, Aaron E. Carnes, C. Hodgson, 2009, Biotechnology advances.

Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene.

R. Coffey, D. Wildrick, G. Gallick, 1993, Cancer research.

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

J. August, M. Gale, James A. Williams, 2010, Journal of Virology.

Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers

J. Williams, U. Gerdemann, A. Leen, 2010, Gene Therapy.

Patent update biologicals and immunologicals: Transgenic animal models and gene therapy

A. Chakraborty, C. Hodgson, D. Cosgrove, 1994 .

Efficient packaging of a specific VL30 retroelement by psi 2 cells which produce MoMLV recombinant retroviruses.

M. Hatzoglou, R. Hanson, C. Hodgson, 1990, Human gene therapy.

Sustained tissue-specific transgene expression from a vl 30 retrotransposon-derived vector in vivo Research Article

C. Hodgson, J. Grunkemeyer, D. Cosgrove, 2004 .

Structure and expression of mouse VL30 genes

D. Foster, P. K. Elder, M. Getz, 1983, Molecular and cellular biology.

Modular retro‐vectors for transgenic and therapeutic use

C. Hodgson, J. Grunkemeyer, D. Cosgrove, 2000, Molecular reproduction and development.

Fusogenic effects of murine retroviruses and cationic enhancers of transduction

C. Hodgson, M. A. Zink, Fauzia Solaiman, 2000, Cancer Gene Therapy.

Retrotransposon Gene Engineering

R. F. Cook, S. Cook, C. Hodgson, 1991, Bio/Technology.

Genomic structure and possible retroviral origin of the chicken CR1 repetitive DNA sequence family.

B. O’Malley, M. Tsai, W. Stumph, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Thermostable tag (TST) protein expression system: engineering thermotolerant recombinant proteins and vaccines.

D. Waugh, James A. Williams, Aaron E. Carnes, 2011, Journal of biotechnology.

Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa.

T. Smyrk, B. Boman, H. Lynch, 1990, Journal of the National Cancer Institute.

Biosynthetic retrovectoring systems for gene therapy

C. Hodgson, M. A. Zink, Fauzia Solaiman, 1997, Journal of Molecular Medicine.

Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.

James A. Williams, Aaron E. Carnes, C. Hodgson, 2009, Vaccine.

Overview: Retroviral Vectors for Gene Therapy and Transgenics

B. Boman, A. Chakraborty, C. Hodgson, 1993 .

A Noncytolytic &agr; Toxin Recombinant Protein Protects Turkeys Against Clostridium septicum Challenge

D. Foster, L. K. Foster, C. Lancto, 2014, Avian diseases.

Hybridization probe size control: optimized 'oligolabelling'.

C. Hodgson, R. M. Fisk, R. Z. Fisk, 1987, Nucleic acids research.

Role of far upstream repressor elements controlling proto-Ha-ras gene transcription.

A. Chakraborty, C. Hodgson, 1998, Biochemical and biophysical research communications.

Liver-specific expression of a phosphoenolpyruvate carboxykinase-neo gene in genetically modified chickens.

R. F. Cook, R. Hanson, S. Cook, 1993, Poultry science.

Synthetic retrotransposon vectors for gene therapy

A. Chakraborty, C. Hodgson, M. A. Zink, 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

RB1 protein in normal and malignant human colorectal tissue and colon cancer cell lines 1

J. Marcus, A. Chakraborty, C. Hodgson, 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Virosomes: Cationic Liposomes Enhance Retroviral Transduction

C. Hodgson, Fauzia Solaiman, 1996, Nature Biotechnology.

The Vector Void in Gene Therapy

C. Hodgson, 1995, Bio/Technology.

Polyadenylylated RNA complementary to a mouse retrovirus-like multigene family is rapidly and specifically induced by epidermal growth factor stimulation of quiescent cells.

H. Moses, L. Schmidt, D. Foster, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Social and Legal Issues of Biotechnology

C. Hodgson, 1987 .

Nucleotide sequence of mouse virus-like (VL30) retrotransposon BVL-1.

C. Hodgson, M. Chotani, R. M. Fisk, 1990, Nucleic acids research.

Polyadenylate‐deficient analogues of poly(A)‐containing mRNA sequences in cultured AKR mouse embryo cells

G. Siegal, P. K. Elder, M. Getz, 1980, Journal of cellular physiology.

Plasmid DNA fermentation strain and process‐specific effects on vector yield, quality, and transgene expression

James A. Williams, Aaron E. Carnes, C. Hodgson, 2011, Biotechnology and bioengineering.

Generic plasmid DNA production platform incorporating low metabolic burden seed‐stock and fed‐batch fermentation processes

James A. Williams, Aaron E. Carnes, C. Hodgson, 2009, Biotechnology and bioengineering.

Plasmid DNA production combining antibiotic‐free selection, inducible high yield fermentation, and novel autolytic purification

James A. Williams, Aaron E. Carnes, C. Hodgson, 2009, Biotechnology and bioengineering.

Patent Update Biologicals & Immunologicals: DNA topoisomerase inhibitors: potential uses in molecular medicine

A. Chakraborty, H. Majumder, C. Hodgson, 1994 .

Retro-Vectors for Human Gene Therapy

C. Hodgson, 1996 .

Discrete regions of sequence homology between cloned rodent VL30 genetic elements and AKV-related MuLV provirus genomes.

P. K. Elder, M. Getz, C. Hodgson, 1983, Nucleic acids research.

Conserved, erythropoietin-responsive VL30 promoters isolated from erythroid progenitor cells.

J. Knezetic, C. Hodgson, W. Staplin, 2002, Blood cells, molecules & diseases.

Critical design criteria for minimal antibiotic‐free plasmid vectors necessary to combine robust RNA Pol II and Pol III‐mediated eukaryotic expression with high bacterial production yields

James A. Williams, Aaron E. Carnes, C. Hodgson, 2010, The journal of gene medicine.

Inducible Escherichia coli fermentation for increased plasmid DNA production

James A. Williams, C. Hodgson, Aaron E. Carnes, 2006, Biotechnology and applied biochemistry.

Patent Update: Biologicals & Immunologicals: Advances in vector systems for gene therapy

C. Hodgson, 1995 .

Casein, actin, and tubulin expression during early involution in bovine and murine mammary tissue.

C. Brooks, C. Hodgson, D. Wiens, 1992, Journal of dairy science.

DNA dose and sequence dependence in sperm‐mediated gene transfer

G. Zaccagnini, C. Spadafora, I. Sciamanna, 2000, Molecular reproduction and development.

pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids.

L. Johnson, James A. Williams, C. Hodgson, 2006, Vaccine.

Strain Engineering by Genome Mass Transfer: Efficient Chromosomal Trait Transfer Method Utilizing Donor Genomic DNA and Recipient Recombineering Hosts

James A. Williams, C. Hodgson, J. Luke, 2009, Molecular biotechnology.

Vector Insert-Targeted Integrative Antisense Expression System for Plasmid Stabilization

James A. Williams, Aaron E. Carnes, C. Hodgson, 2011, Molecular biotechnology.

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

J. August, M. Gale, James A. Williams, 2010, Journal of Virology.

Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy.

A. Chakraborty, C. Hodgson, M. A. Zink, 1994, Cancer gene therapy.